- $117.09m
- $110.87m
- $58.45m
- 50
- 19
- 26
- 23
Annual cashflow statement for TELA Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22.4 | -28.8 | -33.3 | -44.3 | -46.7 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 2.58 | 3.97 | 5.77 | 7.74 | 7.03 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -6.26 | -0.156 | -3.46 | -5.38 | -2.03 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -25.5 | -24.5 | -30.4 | -40.7 | -40.9 |
| Capital Expenditures | -2.7 | -0.167 | -0.627 | -1.87 | -0.611 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -9.28 | 9.29 | 0 | 0 | 0.012 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -12 | 9.12 | -0.627 | -1.87 | -0.599 |
| Financing Cash Flow Items | 0 | -0.522 | 0 | -3.62 | -0.289 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 65.5 | 44.4 | 0.585 | 40.9 | 46.3 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 28 | 29.1 | -30.5 | -1.91 | 4.97 |